Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ETBX-071

Vaccine (Adenoviral vector) · Immune activation, directed at prostate-specific antigen (KLK3) · developed by ImmunityBio

Phase 2 Most advanced trial (none active)

IBRX Developer

2 Registered trials

What is ETBX-071?

ETBX-071 is a replication-deficient adenoviral vaccine encoding prostate-specific antigen (PSA). It infects cells to express PSA, triggering a cytotoxic T-lymphocyte response against PSA-expressing prostate cancer cells. It is studied in high-risk prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Adenoviral vector)
Targets: prostate-specific antigen (KLK3) (antigen)
Mechanism: Immune activation, directed at prostate-specific antigen (KLK3)
Pathways: immune_activation, cytotoxic_T_lymphocyte_response
Therapy area: Oncology
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 68TF9SDE9N

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06765902	Phase 2	High-risk Prostate Cancer	Withdrawn	IBRX
NCT06765954	Phase 2	High-risk Prostate Cancer	Withdrawn	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

High-risk Prostate Cancer

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 CD19 t-haNK Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 GI-4000 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind ETBX-071

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z